Clinical and preclinical studies have demonstrated that the PI3K/AKT pathway is reactivated in ALK-positive NSCLC after Crizotinib and other TKI treatments, often through bypass activation involving EGFR or IGF-1R. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.